Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

TGF-β Decreases NK Cell Mobility and Cytotoxic Efficacy in Complex in vitro Models of the Leukemia Microenvironment

V. Švubová, L. Janstová, M. Jedlička, E. Mašínová, J. Szabová, T. Feglarová, K. Kuglerová, V. Bosáková, B. Brodská, K. Boráková, D. Kundrát, I. Trsová, M. Böhmová, K. Kuželová, J. Hrdý, Z. Gašová, J. Vydra, M. Dostálová Merkerová, M....

. 2025 ; 14 (-) : 589-604. [pub] 20250618

Status neindexováno Jazyk angličtina Země Nový Zéland

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25014142

BACKGROUND: Natural killer (NK) cell-based therapies represent a promising approach for acute myeloid leukemia (AML) relapse, yet their efficacy is hindered by immunosuppressive factors such as transforming growth factor beta (TGF-β) in the tumor microenvironment. This study investigated the effects of TGF-β on NK cell cytotoxicity and migration using 2D and 3D co-culture models that mimic the leukemic microenvironment. METHODS: TGF-β production was evaluated in AML-derived leukemic cell lines and mesenchymal stromal cells (hTERT-MSCs) using ELISA. Bulk RNA sequencing (RNA-seq) was performed to analyze global gene expression changes in TGF-β-treated primary human NK cells. NK cell cytotoxicity and migration were assessed in 2D monolayer and 3D spheroid co-cultures containing hTERT-MSCs and leukemic cells using flow cytometry and confocal microscopy. RESULTS: Both leukemic cells and MSCs produced TGF-β, with increased levels observed in MSCs after co-culture with primary AML blasts. RNA sequencing revealed that TGF-β altered key gene pathways associated with NK cell cytotoxicity, adhesion, and migration, supporting its immunosuppressive role. In functional assays, TGF-β exposure significantly reduced NK cell-mediated cytotoxicity in a time-dependent manner and impaired NK cell infiltration into 3D spheroids, particularly in models incorporating MSCs. Additionally, MSCs themselves provided a protective environment for leukemic cells, further reducing NK cell effectiveness in 2D co-cultures. CONCLUSION: TGF-β suppresses both NK cell cytotoxicity and migration, limiting their ability to eliminate leukemic cells and infiltrate the bone marrow niche (BMN). These findings provide novel insights into TGF-β-mediated immune evasion mechanisms and provide important insights for the future design of NK-based immunotherapies and clinical trials.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25014142
003      
CZ-PrNML
005      
20250905141511.0
007      
ta
008      
250701e20250618nz f 000 0|eng||
009      
AR
024    7_
$a 10.2147/ITT.S512700 $2 doi
035    __
$a (PubMed)40546335
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Švubová, Veronika $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia $u Department. of Cell Biology, Faculty of Science - Charles University, Prague, Czechia $1 https://orcid.org/0009000353911131
245    10
$a TGF-β Decreases NK Cell Mobility and Cytotoxic Efficacy in Complex in vitro Models of the Leukemia Microenvironment / $c V. Švubová, L. Janstová, M. Jedlička, E. Mašínová, J. Szabová, T. Feglarová, K. Kuglerová, V. Bosáková, B. Brodská, K. Boráková, D. Kundrát, I. Trsová, M. Böhmová, K. Kuželová, J. Hrdý, Z. Gašová, J. Vydra, M. Dostálová Merkerová, M. Hortová-Kohoutková, J. Frič
520    9_
$a BACKGROUND: Natural killer (NK) cell-based therapies represent a promising approach for acute myeloid leukemia (AML) relapse, yet their efficacy is hindered by immunosuppressive factors such as transforming growth factor beta (TGF-β) in the tumor microenvironment. This study investigated the effects of TGF-β on NK cell cytotoxicity and migration using 2D and 3D co-culture models that mimic the leukemic microenvironment. METHODS: TGF-β production was evaluated in AML-derived leukemic cell lines and mesenchymal stromal cells (hTERT-MSCs) using ELISA. Bulk RNA sequencing (RNA-seq) was performed to analyze global gene expression changes in TGF-β-treated primary human NK cells. NK cell cytotoxicity and migration were assessed in 2D monolayer and 3D spheroid co-cultures containing hTERT-MSCs and leukemic cells using flow cytometry and confocal microscopy. RESULTS: Both leukemic cells and MSCs produced TGF-β, with increased levels observed in MSCs after co-culture with primary AML blasts. RNA sequencing revealed that TGF-β altered key gene pathways associated with NK cell cytotoxicity, adhesion, and migration, supporting its immunosuppressive role. In functional assays, TGF-β exposure significantly reduced NK cell-mediated cytotoxicity in a time-dependent manner and impaired NK cell infiltration into 3D spheroids, particularly in models incorporating MSCs. Additionally, MSCs themselves provided a protective environment for leukemic cells, further reducing NK cell effectiveness in 2D co-cultures. CONCLUSION: TGF-β suppresses both NK cell cytotoxicity and migration, limiting their ability to eliminate leukemic cells and infiltrate the bone marrow niche (BMN). These findings provide novel insights into TGF-β-mediated immune evasion mechanisms and provide important insights for the future design of NK-based immunotherapies and clinical trials.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Janstová, Lucie $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia
700    1_
$a Jedlička, Marek $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia $u Department. of Cell Biology, Faculty of Science - Charles University, Prague, Czechia
700    1_
$a Mašínová, Eva $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia $u Department. of Cell Biology, Faculty of Science - Charles University, Prague, Czechia
700    1_
$a Szabová, Jana $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia
700    1_
$a Feglarová, Tereza $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia
700    1_
$a Kuglerová, Kateřina $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia
700    1_
$a Bosáková, Veronika $u Department. of Cellular and Molecular Immunoregulation, International Clinical Research Center - St. Anne's University Hospital in Brno (FNUSA-ICRC), Brno, Czechia $u Department. of Biology, Faculty of Medicine - Masaryk University, Brno, Czechia
700    1_
$a Brodská, Barbora $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia $1 https://orcid.org/000000023703594X $7 xx0161159
700    1_
$a Boráková, Kristýna $u Pediatric-neonatal department, Institute for the Care of Mother and Child, Prague, Czechia
700    1_
$a Kundrát, David $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia $1 https://orcid.org/0000000347701229
700    1_
$a Trsová, Iva $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia $u Department. of Genetics and Microbiology, Faculty of Science - Charles University, Prague, Czechia
700    1_
$a Böhmová, Martina $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia
700    1_
$a Kuželová, Kateřina $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia $1 https://orcid.org/0000000296286255 $7 xx0115456
700    1_
$a Hrdý, Jiří $u Institute of Clinical Immunology and Allergology, First Faculty of Medicine, Charles University, Prague, Czechia $u Institute of Clinical Immunology and Allergology, General University Hospital, Prague, Czechia $1 https://orcid.org/0000000306124509 $7 xx0234681
700    1_
$a Gašová, Zdenka $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia
700    1_
$a Vydra, Jan $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia
700    1_
$a Dostálová Merkerová, Michaela $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia
700    1_
$a Hortová-Kohoutková, Marcela $u Department. of Cellular and Molecular Immunoregulation, International Clinical Research Center - St. Anne's University Hospital in Brno (FNUSA-ICRC), Brno, Czechia $u International Clinical Research Center, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Frič, Jan $u Institute of Hematology and Blood Transfusion (IHBT), Prague, Czechia $u Department. of Cellular and Molecular Immunoregulation, International Clinical Research Center - St. Anne's University Hospital in Brno (FNUSA-ICRC), Brno, Czechia $u International Clinical Research Center, Faculty of Medicine, Masaryk University, Brno, Czechia
773    0_
$w MED00216579 $t ImmunoTargets and therapy $x 2253-1556 $g Roč. 14 (20250618), s. 589-604
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40546335 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250701 $b ABA008
991    __
$a 20250905141458 $b ABA008
999    __
$a ok $b bmc $g 2387975 $s 1251262
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 14 $c - $d 589-604 $e 20250618 $i 2253-1556 $m ImmunoTargets and therapy $n ImmunoTargets ther. $x MED00216579
LZP    __
$a Pubmed-20250701

Najít záznam

Citační ukazatele

Možnosti archivace